2009-03-10 13:52:14 -
Depomed, Inc. (NASDAQ:DEPO) announced today that president and chief executive officer, Carl A. Pelzel will be presenting at the Cowen and Company 29th Annual Healthcare Conference in Boston, Massachusetts on Tuesday, March 17, 2009 at 3:10 p.m. ET.
The company will be webcasting its presentation and interested parties can access the live or archived presentation for up to
90 days on the company's website at www.depomed.com.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuFormTM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate DM-5689 is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, www.depomedinc.com.
Depomed, Inc.
Sheilah Serradell, 650-462-5900
sserradell@depomed.com 
